Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice
The survival of most patients with advanced stage non-small cell lung cancer is prolonged by several months when they are treated with first- and next-generation inhibitors targeting <i>ALK </i>rearrangements, but resistance inevitably emerges. Some of the mechanisms of resistance are se...
Main Author: | Paul Hofman |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/1/168 |
Similar Items
-
ALK Status Assessment with Liquid Biopsies of Lung Cancer Patients
by: Paul Hofman
Published: (2017-08-01) -
Liquid Biopsy and Therapeutic Targets: Present and Future Issues in Thoracic Oncology
by: Paul Hofman
Published: (2017-11-01) -
NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
by: Estela Sánchez‐Herrero, et al.
Published: (2021-09-01) -
Future Perspectives in Detecting <i>EGFR</i> and <i>ALK</i> Gene Alterations in Liquid Biopsies of Patients with NSCLC
by: Daniela Ferreira, et al.
Published: (2021-04-01) -
Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report
by: Yingying Zhu, et al.
Published: (2020-07-01)